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Abstract: Pembrolizumab, an anti-programmed cell death (PD)-1 monoclonal antibody, is an anticancer
agent showing substantial benefit in lung cancer and melanoma treatment. Biliary tract cancer (BTC)
has been shown to respond to pembrolizumab; however, no credible data of such treatment outcomes
exist. Therefore, we assessed the clinical outcomes and safety of pembrolizumab in patients with
gemcitabine/cisplatin-refractory BTC. In this multicenter study, we retrospectively analyzed 51 patients
with programmed cell death 1-ligand 1 (PD-L1)-positive gemcitabine/cisplatin-refractory BTC treated
with pembrolizumab in four tertiary hospitals in Korea. PD-L1 positivity was defined as the expression
of PD-L1 in≥1% of tumor cells based on immunohistochemical staining (22C3, SP263, and E1L3N assays).
The median age of the patients was 66 (range, 43–83) years and 29 (56.9%) were male. Extrahepatic
cholangiocarcinoma was the most common cancer type (n = 30, 58.8%). Partial response and stable
disease were achieved in 5 (9.8%) and 13 (25.5%) patients, respectively. Median progression-free survival
and overall survival were 2.1 (95% CI, 1.7–2.4) and 6.9 (95% CI, 5.4–8.3) months, respectively. Overall,
30 (58.8%) patients experienced treatment-related adverse events (AEs). Only four (7.8%) patients
experienced grades 3 and 4 AEs. In PD-L1-positive gemcitabine/cisplatin-refractory BTC, pembrolizumab
presented durable efficacy, with a 9.8% response rate and manageable toxicity.
Keywords: biliary tract neoplasm; cholangiocarcinoma; immunotherapy; PD-L1 costimulatory
protein; biomarker
1. Introduction
Biliary tract cancers (BTCs) consist of all tumors originating in the epithelial cells of the bile duct
and they are classified into intrahepatic cholangiocarcinoma (CCA), extrahepatic CCA (including
perihilar and distal CCA), and gallbladder cancer, according to their anatomical location within the
biliary tree. More than 90% of BTCs are adenocarcinoma. Although the incidence of BTC is the
highest in East and South Asia and parts of South America, its global incidence has been increasing
significantly [1,2]. Surgical resection is regarded as the curative treatment option for patients with BTC
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but most patients are not considered suitable candidates for surgery because of an advanced disease
status at diagnosis [3,4]. Patients with advanced BTC have a poor prognosis with a dismal survival
time of <1 year [5,6]. Recent updated guidelines recommend gemcitabine plus cisplatin as the first-line
chemotherapy for patients with advanced BTC [4,7]. However, effective treatment options for patients
with gemcitabine/cisplatin-refractory BTC are currently limited [8].
Pembrolizumab, an anti-programmed cell death (PD)-1 monoclonal antibody, is an anticancer agent
that has shown substantial benefit in patients with lung cancer and melanoma [9–11]. Following the
discovery of the PD-1/PD-1-ligand 1 (PD-L1) pathway as an immunological target to control cancer,
immune checkpoint inhibitors, including pembrolizumab, have been designed to overcome the
inhibitory responses of cytotoxic T lymphocytes to promote antitumor immune responses [12–14].
The first related study showed a notable clinical effect of pembrolizumab in patients with non-colorectal
cancer, including four with BTC with mismatch repair (MMR) deficiency, with a 71% objective response
rate (ORR) [13]. In a few subsequent studies, pembrolizumab was reported to be effective against
advanced BTC, targeting a subpopulation with more than 1% PD-L1 expression in tumors [15,16].
However, there are no credible data of the treatment outcomes of pembrolizumab against BTC. In the
present multicenter retrospective study, we investigated the clinical outcomes and safety profile of
pembrolizumab in patients with gemcitabine/cisplatin-refractory BTC using PD-L1 positivity as a
response biomarker and attempted to identify a subpopulation that would potentially benefit from
this treatment.
2. Patients and Methods
2.1. Study Population
From August 2017 to April 2019, 65 patients with PD-L1-positive gemcitabine/cisplatin-refractory
BTC who received pembrolizumab were included in this multicenter study with the following inclusion
criteria: (1) ≥20 years of age; (2) histologically or cytologically confirmed locally advanced or metastatic
BTC; (3) at least one measurable or evaluable lesion according to Response Evaluation Criteria in
Solid Tumors (RECIST) version 1.1 [17]; (4) radiologically confirmed presence of progressive disease or
intolerance to gemcitabine/cisplatin chemotherapy; (5) ≥1% PD-L1-positive tumor cells as assessed
using immunohistochemical (IHC) staining; and (6) receipt of at least one cycle of pembrolizumab.
Fourteen patients were excluded according to the following criteria: (1) diagnosis of ampulla
of Vater cancer (n = 1); (2) inability to assess tumor response (n = 6); (3) no gemcitabine/cisplatin
chemotherapy before pembrolizumab injection (n = 4); and (4) no PD-L1 IHC-staining examination
(n = 3). Fifty-one patients (41 from Severance Hospital, Seoul, Korea; 4 each from Seoul National
University Hospital, Seoul, Korea, and National Cancer Center, Goyang, Korea; and 2 from Pusan
National University Hospital, Busan, Korea) were included in the final analysis. Among them,
44 patients (86.3%) were radiologically confirmed to have progressive disease, and another 7 (13.7%)
were intolerant to gemcitabine/cisplatin chemotherapy. All the clinical, laboratory and radiologic data
were collected from electronic medical records and were retrospectively reviewed without obtaining
informed consent. The study was approved by the institutional review board of each institution
(Severance Hospital Institutional Review Board, Seoul National University Hospital Institutional
Review Board, National Cancer Center Institutional Review Board, and Institutional Review Board of
Pusan National University Hospital).
2.2. PD-L1 IHC Assay
PD-L1 expression was assessed by conducting an IHC staining of achieved tumor tissues before
systemic treatment, using the E1L3N (Cell Signaling Technology, Danvers, MA, USA), 22C3 (Agilent
Technologies, Santa Clara, CA, USA), and SP263 (Ventana Benchmark Ultra, Tuscon, AZ, USA) assays.
PD-L1-positive tumor cells were considered if the viable tumor cells exhibited any perceptible, partial or
complete, membranous or cytoplasmic staining, as previously described [18]. PD-L1-positive status
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was defined based on a 1% threshold in immunostained tumor cells in the entire tumor section by any
IHC method. The frequency of use of the E1L3N, 22C3, and SP263 IHC assays was as follows: n = 33
(57.9%), 27 (47.4%), and 9 (15.8%), respectively. PD-L1 expression was categorized into three subgroups
based on the proportion of immunostained tumor cells using additional cutoff values of 5% and 50%.
2.3. Treatment Schedule and Response Evaluation
All patients received 200 mg pembrolizumab intravenously, every 3 weeks after a 17-day
median interval from the last prior treatment. Dose reduction, administration delay, or both were
performed if serious treatment-related adverse events (AEs) developed, making treatment intolerable.
Pembrolizumab administration was interrupted when disease progression or life-threatening AEs
were identified. To evaluate treatment efficacy, we routinely evaluated the tumor response every three
cycles using abdominal or chest computed tomography or both according to RECIST version 1.1 [17].
2.4. Assessment of Treatment-Related AEs
To monitor treatment-related AEs, physicians and registered nurses meticulously evaluated the
occurrence of AEs at each visit during treatment. The category and severity grade of the AEs were
accurately recorded in the medical records of the patients. Treatment-related AEs were evaluated
according to National Cancer Institute Common Toxicity Criteria version 4.0. Treatment delays or
discontinuations associated with the AEs were also documented with the reason.
2.5. Study Endpoints and Statistical Analysis
The primary endpoint of this study was response rate and the secondary endpoints were
AEs, progression-free survival (PFS), and overall survival (OS). Tumor responses included complete
response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). DCR was
defined as the summation of CR, PR, and SD. PFS was defined as the time from the initiation of
pembrolizumab treatment to disease progression or date of death, and OS was defined as the time from
the initiation of pembrolizumab treatment to the date of death due to any cause or the last follow-up
visit. The last follow-up date was 31 September 2019, and the median follow-up duration was 3.8
(range, 0.6–18.4) months.
Data are expressed as the mean ± standard deviation, median (range), or n (%), as appropriate.
A survival analysis for PFS and OS was performed using the Kaplan-Meier method and compared using
the log-rank test. To identify independent risk factors for progression, we performed a multivariate
Cox proportional hazard regression analysis using the significant variables in the univariate analysis.
Hazard ratios (HRs) and the corresponding 95% confidence intervals (CI) were also calculated.
A two-tailed p-value of 0.05 was considered statistically significant, and the statistical analysis was
performed using SPSS version 25.0 (PASW Statistics Inc., Chicago, IL, USA).
3. Results
3.1. Baseline Characteristics
The baseline characteristics of the 51 enrolled patients are presented in Table 1. The median
age was 66 (range, 43–83) years and 29 (56.9%) patients were male. Extrahepatic CCA was the most
common type of cancer (n = 30, 58.8%), followed by intrahepatic CCA (n = 12, 23.5%) and gallbladder
cancer (n = 9, 17.6%). All patients were diagnosed with adenocarcinoma, histologically or cytologically.
Most patients were diagnosed at a metastatic stage (n = 45, 88.2%), including 28 with post-operative
recurrence. Common organs of distant metastasis were as follows: liver (n = 24, 47.1%), intra-abdominal
lymph node (n = 24, 47.1%), peritoneal seeding (n = 17, 33.3%), bone (n = 4, 7.8%), and lungs (n = 2,
3.9%). Histological grading was moderately and poorly differentiated in 28 (54.9%) and 14 (27.5%)
patients, respectively. Subgrouping based on the proportion of PD-L1-positive tumor cells with cutoff
values of 5% and 50% revealed that low (1–5%), moderate (5–50%), and high (≥50%) PD-L1 subgroups
J. Clin. Med. 2020, 9, 1769 4 of 10
accounted for 35 (68.6%), 11 (21.6%), and 5 (9.8%) patients, respectively. The median carbohydrate
antigen (CA) 19-9 level was 276.6 U/mL (range, 1.1–24,253.0). Pembrolizumab was administered as the
second, third, and fourth or greater line chemotherapy in 33 (64.7%), 14 (27.5%), and 4 (7.8%) patients,
respectively. A median of three cycles (range 1–15) of pembrolizumab was administered during a
median of 3.8 (range, 0.6–18.4) months of follow-up.
Table 1. Baseline characteristics of patients.
Characteristics
Age (years) 66 (43–83)
Sex (male) 29 (56.9%)
Performance status
ECOG 0/1/2 24 (47.1%)/24 (47.1%)/3 (5.9%)
Location
Intrahepatic/extrahepatic/gallbladder 12 (23.5%)/30 (58.8%)/9 (17.6%)
Stage
Locally advanced/metastatic 6 (11.8%)/45 (88.2%) †
Organ of metastasis
Liver 24 (47.1%)
Intra-abdominal lymph node 24 (47.1%)




Well/moderate/poorly/unknown 3 (5.9%)/28 (54.9%)/14 (27.5%)/6 (11.8%)
PD-L1-positive (≥1%) 51 (100%)
1–5/5–50/≥50 35 (68.6%)/11 (21.6%)/5 (9.8%)
Laboratory results
Hemoglobin (g/dL) 10.3 ± 1.8
Albumin (g/dL) 3.6 ± 0.5
AST (IU/L) 32 ± 19
ALT (IU/L) 35 ± 63
Total bilirubin (mg/dL) 0.72 ± 0.51
CA 19-9 (U/mL) 276.6 (1.1–24,253.0)
Clinical information
Number of prior therapies (1/2/≥3) 33 (64.7%)/14 (27.5%)/4 (7.8%)
Cycles of pembrolizumab 3.0 (1–15)
≤3/>3 33 (64.7%)/27 (35.3%)
Combination treatment 1 (2.0%) ‡
Follow-up duration (months) 3.8 (0.6–18.4)
Patients, n = 51, † including 28 with post-operative recurrence. ‡ One patient who concurrently received palliative
radiation therapy for cervical LN metastasis. Abbreviations: ECOG, Eastern Cooperative Oncology Group; PD-L1,
programmed cell death 1-ligand 1; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CA 19-9,
carbohydrate antigen 19-9.
3.2. Clinical Outcomes and AEs
In the 51 patients enrolled, PR and SD were achieved in 5 (9.8%) and 14 (25.5%) patients,
respectively (Table 2), whereas the DCR was 35.2%. In five patients with PR, the median time to
response was 2.5 (range, 2.1–8.3) months and the median duration of treatment was 9.1 months.
Five patients with PR exhibited 1, 2, 5, 10, and 50% of PD-L1 expression level. Overall, the median PFS
and OS were 2.1 (95% CI, 1.7–2.4) and 6.9 (95% CI, 5.4–8.3) months, respectively (Figure 1). Figure 2
illustrates the changes in tumor size from the baseline to the best response in 42 patients. When the
study population was divided into three subgroups based on PD-L1 expression, this did not appear to
be significantly associated with the best tumor response (Figure 2)
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Table 2. Clinical outcomes.
Variable
Partial response 5 (9.8%)
Stable disease 13 (25.5%)
Progression disease 33 (64.7%)
Disease control rate 35.3%
Time to response (months) † 2.5 (2.1–8.3)
Progression-free survival (months) 2.1 (95% CI 1.7–2.4)
Overall survival (months) 6.9 (95% CI 5.4–8.3)
Patients, n = 51, † Evaluation in five patients with a partial response.
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Figure 2. Tumor response and programmed death-ligand 1 (PD-L1) subgroups of evaluable patients
(n = 42). The highest percentage changes in the size of tumor target lesions from the baseline, measured
using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for the 42 evaluable patients, are shown
by PD-L1 subgroups. * Eleven patients with progressive disease based on RECIST 1.1 due to the
unequivocal progression of non-target lesions despite <20% growth in target lesions.
Overall, 30 (58.8%) patients experienced treatment-related AEs, with fatigue (n = 11, 21.6%, Table 3)
being the most common. Four (7.8%) patients experienced grade 3 and 4 AEs (consisting of grade 3
nausea, fatigue, poor oral intake, diarrhea, and drug-induced pneumonitis) and two patients (3.9%)
discontinued pembrolizumab treatment owing to AEs. There was no case of treatment-related death.
Table 3. Adverse events (AEs).
Variable Any Grade Grade 3/4
Adverse event 30 (58.8%) 4 (7.8%)
Non-hematologic
Fatigue 11 (21.6%) 1 (2.0%)
AST/ALT elevation 8 (15.7%) 0
Nausea 5 (9.8%) 1 (2.0%)
Poor oral intake 3 (5.9%) 2 (3.9%)
Skin rash 3 (5.9%) 0
Diarrhea 2 (3.9%) 1 (2.0%)
Hypothyroidism 2 (3.9%) 0
Peripheral neuropathy 2 (3.9%) 0
Fever 1 ( .0%) 0
Facial ed ma 1 ( .8%) 0
Dizziness 1 ( .8%) 0
Dyspnea 1 (1.8%) 0
Drug-induced pneumonitis 2 (3.5%) 2 (3.9%)
Hematologic
Anemia 3 (5.9%) 0
Thrombocytopenia 3 (5.9%) 0
Patients, n = 51; AST, aspartate aminotransferase; ALT, alanine aminotransferase.
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3.3. Factors Associated with Progression
Univariate analysis showed that the number of prior therapies (≥2), hemoglobin level (<10 g/dL),
and CA 19-9 level (>500 U/mL) were significantly associated with progression (Table 4). Subgroups
based on PD-L1 expression could not be used to predict progression after pembrolizumab treatment.
Although the subsequent multivariate analysis did not identify statistically significant predictors of
progression, patients receiving pembrolizumab as second-line chemotherapy with a normal hemoglobin
level tended to exhibit favorable PFS (p = 0.069 and p = 0.062, respectively).
Table 4. Predictors of progression after pembrolizumab treatment.
Variable
Univariate Multivariate
p-Value HR (95% CI) p-Value
Sex (male) NS
Age (>65 years) NS
ECOG (>1) NS
Tumor location (intrahepatic CCA) NS
Stage (metastatic) NS
Histological grade (poorly differentiated) † NS
PD-L1 group (1–5% vs. 5–50% vs. ≥50%) NS
Number or prior therapy (≥2) 0.018 1.917 (0.950–3.866) 0.069
Hemoglobin (<10 g/dL) 0.030 1.972 (0.966–4.026) 0.062
Albumin (<3.5 g/dL) NS
CA 19-9 (>500 U/mL) 0.013 1.751 (0.822–3.727) 0.146
Patients, n = 51; † excluding six cases of unknown histological grading. Abbreviations: HR, hazard ratio;
CI, confidence interval; NS, not significant; CCA, cholangiocarcinoma; PD-L1, programmed cell death 1-ligand 1;
CA 19-9, carbohydrate antigen 19-9.
4. Discussion
In this multicenter study, pembrolizumab showed durable antitumor activity, with a 9.8% response
rate and manageable toxicity in patients with PD-L1-positive gemcitabine/cisplatin-refractory BTCs.
The first BTC cohort from the KEYNOTE-028 open-label, phase I clinical trial, which included patients
with 20 different types of solid cancers with PD-L1 expression of >1% (determined by IHC-based assay),
revealed an ORR of 17% (one CR and three PR) and a DCR of 34% (four additional SD) among 23 patients
with BTC [15,19]. The results of another prospective cohort study of 40 patients with BTC with similar
characteristics in a single medical institution showed an OCR of 10.0% (four patients with PR) and a DCR
of 47.5% (additional 15 patients with SD) [16]. Our study had a larger population scale than these two
studies but showed a similar overall response rate (Table 5). Intriguingly, some patients who responded
showed a long duration of treatment: >6 months (median 9.1 months in our study; 6.3 months [16] and
2-year duration of treatment of 67% [15] and 50% [20] patients, respectively, in other studies).
Table 5. Reported data of pembrolizumab treatment in patients with gemcitabine/cisplatin-refractory
biliary tract cancer (BTC).











Ott et al. (2019) [15,19] 23 4 (17%) 8 (34%) 1.8 6.2 15 (63%) 4 (17%)
Kang et al. (2019) [16] 40 4 (10.0%) 19 (47.5%) 1.5 4.3 8 (20.5%) 0 (0%)
Our data 51 5 (9.8%) 19 (35.2%) 2.1 6.9 30 (58.8%) 4 (7.8%)
Abbreviations: BTC, biliary tract cancer; ORR, objective response rate; DCR, disease control rate; PFS, progression-free
survival; OS, overall survival; AE, adverse event.
The interim report of KEYNOTE-158, the largest ongoing phase II, single-arm, open-label cohort
study of pembrolizumab in patients with various types of advanced cancers, including 104 patients
with BTC, was published in 2018 [20]. The 104 patients with BTC showed an ORR of only 5.8%,
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including 0, 6, and 17 patients with CR, PR, and SD, respectively (DCR was 22.1%) [20]. This cohort
study included 61 and 31 patients with PD-L1-positive and PD-L1-negative expression, respectively.
Interestingly, PD-L1 expression did not predict treatment response and this is similar to the findings of
our study. Although the ORR was slightly higher in the PD-L1-positive group than in the negative
group (6.6% vs. 2.9%), there were no significant differences in the median PFS (1.9 vs. 2.1 months) or
OS (7.2 vs. 9.6 months) [20]. This result, which showed the limited clinical efficacy of pembrolizumab
monotherapy in advanced BTC, encouraged us to explore biomarkers to identify a subpopulation
likely to respond and a new therapeutic strategy to overcome the limited antitumor response in BTC.
The IHC analysis of PD-L1 expression predicts the clinical efficacy of immune checkpoint inhibitors
in several cancers [16,21–23]. In particular, in non-small-cell lung cancer, the cutoff value of PD-L1
was lowered from 50% to 1%, and immune checkpoint inhibitors are now considered as the first-line
treatment for advanced stage tumor with or without conventional chemotherapy [21,23,24]. Recently,
Kang et al. suggested that a high cutoff value of ≥50% could predict tumor response when evaluated
by immune-modified RECIST criteria [16]. In addition, a Japanese phase I study of another PD-L1
inhibitor, nivolumab, reported that PD-L1-positive patients (≥1%) had longer median PFS (2.8 vs.
1.4 months) and OS (11.6 vs. 5.2 months) than those of PD-L1-negative patients among 30 patients
with gemcitabine-refractory advanced BTC [25]. These findings, however, resulted from preliminary
studies with relatively small-sized study populations and did not correspond with the results of
KEYNOTE-158 or our study [20]. Furthermore, our analysis of several clinical factors to validate
another response predictor of pembrolizumab revealed few prior therapies and normal hemoglobin
level as predictors of a favorable tendency to respond, without statistical significance in the multivariate
analysis. Hence, the usefulness of these factors, including tumor PD-L1 status, should be verified in
large-scale, prospective clinical trials in the future.
An established biomarker for patients’ response to immune checkpoint inhibitors is the neo-antigen
tumor burden resulting from microsatellite instability (MSI) owing to MMR deficiency (MSI-high/
MMR-deficiency) [26]. The genomic spectra of BTC have shown the presence of MSI in a small portion of
approximately 1–2% [26–29]. The clinical results of pembrolizumab monotherapy in advanced MSI-high/
MMR-deficient cancers, including 4 and 11 patients with BTC, demonstrated ORR values of 25% and 27%,
respectively, for a subset of patients with BTC with a response duration of >6 months [13,30]. However, we
could retrospectively assess the MSI status in seven (13.7%) patients in our study population, none with
MSI-H/MMR-deficiency.
To evaluate the significant response biomarker, the KEYNOTE-028 (NCT02054806) study analyzed
multiple biomarkers including expression of an 18-gene T cell-inflamed profile, PD-L1 expression,
and tumor mutational burden. All three factors (alone or combined) were correlated with high
response rate to pembrolizumab in the overall study population of multiple tumor types [19]. However,
biomarker data specific for BTC has not been indubitably presented until now.
The safety profile of pembrolizumab in this study was generally consistent with that in previous
studies [9,13,15,16]. Four (7.8%) patients experienced grade 3 AEs with 50% (n = 2, 3.9%) treatment
discontinuation in our study. Two patients with pneumonitis associated with immune checkpoint
inhibition were conservatively managed with one week of hospitalization. There are some limitations
in our study. Although all patients in the study were enrolled in a number of tertiary care hospitals,
the possibility of selection bias cannot be excluded due to its retrospective nature. The relatively small
study population may also be insufficient to perform a statistically robust analysis. Additionally,
inconsistent IHC assay methods could serve as a limitation for further investigation.
In conclusion, pembrolizumab monotherapy in patients with gemcitabine/cisplatin-refractory
BTC and PD-L1 positivity showed long-lasting anticancer effects in approximately 10% of the study
population with an overall manageable safety profile. Intensity of PD-L1 expression was not supposed
to an effective surrogate marker for the efficacy of pembrolizumab; therefore, further investigation is
needed to confirm an appropriate biomarker for selecting the subpopulation of advanced BTC patients
who might be sensitive to immune checkpoint inhibitors.
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